Alcon Research
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alcon Research sits in the top decile of US sponsors by registered trial count (#124 of 15,742 sponsors by registered trial count).
Alcon Research: 275 sponsored US clinical trials, 5 recruiting.
Alcon Research sponsors 275 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 248 completed. 87 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cataract, with 12 trials.
Top-decile sponsor footprint
Alcon Research ranks in the top decile of sponsors by registered trial count (#124 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
248 of 266 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
275 total, page 5 of 6
Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost
NCT00637130
DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus
NCT00712244
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
NCT00578929
Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3
NCT00719732
IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00527501
AcrySof Toric Clinical Results
NCT01214863
Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis or Acri.LISA
NCT00721253
Surgeon Experience ReSTOR A +4 Intraocular Lens (IOL)
NCT00733512
Visual Performance of Bilateral AcrySof ReSTOR Aspheric +4
NCT01215045
Intraoperative Floppy Iris Syndrome
NCT00711347
Staining in a Healthy, Non-Dry Eye Population
NCT00643942
Low Cylinder Toric
NCT00732030
ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)
NCT00684138
Contralateral ReSTOR / Monofocal or Phakic Eye
NCT00731640
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
NCT00444665
Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL
NCT00759096
Visual Function and Patient Satisfaction After Bilateral Implantation of AcrySof Natural ReSTOR (Model SN60D3) or AcrySof Natural Monofocal (Model SN60AT)
NCT00759668
DisCoVisc Comparative Evaluation
NCT00732225
Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers
NCT00468988
Visual Function After Bilateral Implantation of AcrySof® Toric
NCT00758550
A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension
NCT00465803
Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00465621
Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma
NCT00451152
Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens
NCT00762021
Safety Study of Olopatadine Nasal Spray
NCT00578331
A Clinical Study of Tobradex AF
NCT00473070
Visual Function After Implantation of Bilateral AcrySof® Toric Natural Intraocular Lens
NCT00760487
Prevalence of Ocular Surface Disease in Glaucoma Patients
NCT00382122
Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension
NCT00300079
Safety/Efficacy of Systane Free vs Refresh Tears
NCT00348322
Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye
NCT00471419
Safety of NGOIS Compared to BSS Plus in Pediatric Patients
NCT00346528
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
NCT00312338
Compliance With Once Daily Glaucoma Medication
NCT00333463
AL-15469A for the Treatment of Bacterial Conjunctivitis
NCT00332293
A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00372931
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00326092
Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
NCT00763061
Fluorophotometry Evaluation of Lubricant Eye Drops
NCT00347854
A Bioequivalence Study of Tobradex AF
NCT00362895
A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief
NCT00330798
Nevanac 3-Month Safety Study With QID Dosing
NCT00332774
Randomized Contralateral Clinical Trial With Single-piece (SN60WF) vs. Three Piece (MA60AC) AcrySof Intraocular Lenses (IOLs) on Development of Posterior Chamber Opacification (PCO).
NCT00758745
A Long-term Safety Study of Once-daily Travatan
NCT00051168
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
NCT00315640
Product Preference With Systane Compared to Artificial Tears on Frequency of Drop Use
NCT00347984
AL-15469A for the Treatment of Bacterial Conjunctivitis
NCT00331916
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00287521
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00314158
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
NCT00333203
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 23 |
| Phase 3 | 47 |
| Phase 4 | 40 |
Therapeutic Areas
Where Alcon Research enrollment is open (later-stage tilt)
5 recruiting of 275 indexed (2% open); 248 completed (90%).
Phase mix: 87 late (III/IV) vs 28 early (I/II) (later-stage heavy).
Top condition: Cataract (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alcon Research: open-pipeline peers nationwide
Peers matched on 275 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Alcon Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 275 trials (± recruiting share)
- Boston Scientific Corporation · 280 trials · 8% recruiting
- Regeneron Pharmaceuticals · 280 trials · 22% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
- Novartis · 265 trials · 0% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · 2% recruiting · 55 trials
- Lexicon Pharmaceuticals · 2% recruiting · 56 trials
- Société des Produits Nestlé (SPN) · 2% recruiting · 53 trials
- Eisai · 2% recruiting · 287 trials
Related
What to do with this Alcon Research page
275 registered trials is a research-attention snapshot, not an endorsement of Alcon Research or any single study.
- 5 of Alcon Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cataract is the condition Alcon Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cataract trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alcon Research pipeline card: 275 registered trials from official public datasets.Report a data error.